Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Candesartan in the prevention of relapsing atrial fibrillation

Trial Profile

Candesartan in the prevention of relapsing atrial fibrillation

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2011

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Atrial fibrillation
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms CAPRAF
  • Most Recent Events

    • 05 Jan 2007 Status change
    • 19 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top